Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.57 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574325 | 0.93 | ADORA3 (0.61) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573844 | 0.88 | ADORA3 (0.64) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573603 | 0.87 | ADORA3 (0.62) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574360 | 0.87 | ADORA3 (0.55) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29575015 | 0.86 | ADORA3 (0.57) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573555 | 0.85 | ADORA3 (0.64) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574506 | 0.82 | ADORA3 (0.75) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL30480245 | 0.82 | ADORA3 (0.57) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573461 | 0.82 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL12805062 | 0.81 | ADORA3 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |